Testing a new immune therapy with or without a growth-blocking drug for aggressive brain tumors

Plain-English translation of NCT07468136 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a medication called , which helps your immune system fight cancer cells in aggressive brain tumors. Some patients will receive alone, while others will receive it combined with a second medication (difluoromethylornithine, or DFMO) that works by blocking signals that tell tumor cells to multiply. All patients will also have surgery as part of their standard care.

Aggressive brain tumors are hard to treat and often come back even after surgery and other treatments. Researchers believe that helping the immune system recognize and attack cancer cells may offer patients a better chance of controlling their disease.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with a high-grade glioma (an aggressive brain tumor), including glioblastoma or high-grade astrocytoma or oligodendroglioma
your brain tumor is growing or spreading on imaging scans
you are well enough to receive cancer treatment (your doctor will assess this using standard performance scales)
you plan to have brain surgery as part of your regular care for this tumor

You likely don't qualify if…

you are pregnant, nursing, or unwilling to use effective birth control during the study
you have an active infection or recent history of immune-related lung disease that required steroids
you have an active autoimmune disease that needed treatment in the past 2 years
you have uncontrolled heart problems, such as unstable chest pain or heart failure
your blood counts or liver and kidney function are too low or too high for safe treatment

What participation looks like

You will receive the medication by IV infusion before your scheduled brain surgery. After surgery, you will continue receiving the medication regularly (every 28 days) for up to 16 additional cycles, along with blood tests and MRI scans to monitor how you're doing. Depending on which group you're assigned to, you may also take an oral medication three times daily. The entire active treatment phase lasts about 4–5 months, and you'll need to be able to return to the hospital for regular check-ups.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Testing a new immune therapy with or without a growth-blocking drug for aggressive brain tumors

What is this trial?

Do you qualify?

What participation looks like

Trial locations